IL-1诱导肝癌小鼠炎症及免疫反应的实验研究

Experimental study on inflammation and immune response induced by IL-1 in liver cancer mice

目的通过建立肝癌小鼠模型,观察IL-1刺激肝癌小鼠后对肝癌炎症及免疫微环境的影响。方法饲养20只NPG级小鼠,予SMMC-7721肝癌细胞在肝包膜下直接接种,待瘤体长出后,随机分为IL-1干预组和对照组,ELISA方法观察IL-10和IL-8干预前后的表达,流式细胞术观察CD4+和CD25+的表达情况。结果小鼠有17只成瘤,成瘤率为85%。把17只成瘤小鼠分为对照组7只,干预组10只;干预组予IL-1腹腔连续注射3d后发现有6只瘤鼠死亡,4只精神萎靡,5d后小鼠全部死亡;对照组小鼠无死亡情况。IL-8在干预后的表达较干预前明显上调(P<0.05),IL-10在干预后的表达较干预前升高,但两组比较,差异无统计学意义(P>0.05)。CD4+CD25+占CD4+的比值在干预后的表达均较干预前有上调(P<0.05)。结论肝癌小鼠内存在炎症和免疫反应,IL-1可以诱导肝癌小鼠的炎症和免疫反应强化。

Objective To establish a mouse model of liver cancer to observe the effects on the inflammation and immune microenvironment of liver cancer in mice stimulated by IL-1.Methods Atotal of twenty NPG mice were bred and inoculated directly under the liver capsule with smmc-7721 hepatocarcinoma cell line.After tumor growth,they were randomly divided into the IL-1 intervention group and the non-intervention group.The expressions of IL-10 and IL-8 before and after intervention were observed by ELISA,and the expressions of CD4+and CD4+CD25+were observed by flow cytometry.Results Tumorigenesis rate was 85%in 20 NPG mice.The 17 tumor-forming nude mice were divided into control group(7)and intervention group(10).After 3 days of continuous intraperitoneal injection of IL-1,6 mice in the intervention group died and 4 mice were found to be listless.All the mice died on the fifth day.The control group had no death.Expression of IL-8,IL-10 and CD4+CD25+were detected in the control group.IL-8 after the intervention of expression significantly raised(P<0.05),compared with before,IL-10 after the intervention in the expression of a higher before and after the intervention,but no obvious difference compared the two groups(P>0.05).The expression of CD4+CD25+/CD4+after intervention have been raised(P<0.05),compared with before.Expression of IL-8,IL-10 and CD4+CD25+were detected in the control group.Conclusion There are inflammatory and immune responses in liver cancer mice,and IL-1 can induce inflammation and immune enhancement in liver cancer mice.